by GlobeNewsWire | Jul 28, 2016 | Globe Newswire
MENLO PARK, Calif., July 28, 2016 (GLOBE NEWSWIRE) — Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone...
by GlobeNewsWire | Apr 1, 2016 | Globe Newswire
MENLO PARK, Calif., April 01, 2016 (GLOBE NEWSWIRE) — Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone...
by GlobeNewsWire | Dec 16, 2015 | Globe Newswire
MENLO PARK, Calif., Dec. 16, 2015 (GLOBE NEWSWIRE) — Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone...
by GlobeNewsWire | Oct 1, 2015 | Globe Newswire
MENLO PARK, Calif., Oct. 1, 2015 (GLOBE NEWSWIRE) — Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone...
by GlobeNewsWire | Sep 10, 2015 | Globe Newswire
MENLO PARK, Calif., Sept. 10, 2015 (GLOBE NEWSWIRE) — Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone...